# A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

> **NCT07104721** · PHASE1 · RECRUITING · sponsor: **China Immunotech (Beijing) Biotechnology Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Lupus Nephritis (LN)
- Systemic Sclerosis (SSc)
- Inflammatory Myopathy
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Antiphospholipid Syndrome (APS)

## Interventions

- **DRUG:** YTS109 cell

## Key facts

- **NCT ID:** NCT07104721
- **Lead sponsor:** China Immunotech (Beijing) Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-04
- **Primary completion:** 2026-08-04
- **Final completion:** 2028-12-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07104721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07104721, "A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07104721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*